These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32123106)

  • 1. bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA).
    Lim S; Khoo R; Peh KM; Teo J; Chang SC; Ng S; Beilhartz GL; Melnyk RA; Johannes CW; Brown CJ; Lane DP; Henry B; Partridge AW
    Proc Natl Acad Sci U S A; 2020 Mar; 117(11):5791-5800. PubMed ID: 32123106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCNA degradation exhibits superior pharmacological effects over stoichiometric inhibition.
    Basu AA; Riha IA; Zhang X
    Cell Chem Biol; 2022 Nov; 29(11):1571-1573. PubMed ID: 36400001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redirecting the specificity of tripartite motif containing-21 scaffolds using a novel discovery and design approach.
    VanDyke D; Xu L; Sargunas PR; Gilbreth RN; Baca M; Gao C; Hunt J; Spangler JB
    J Biol Chem; 2023 Dec; 299(12):105381. PubMed ID: 37866632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E3 ubiquitin ligase HECW2 targets PCNA and lamin B1.
    Krishnamoorthy V; Khanna R; Parnaik VK
    Biochim Biophys Acta Mol Cell Res; 2018 Aug; 1865(8):1088-1104. PubMed ID: 29753763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct role for proliferating cell nuclear antigen in substrate recognition by the E3 ubiquitin ligase CRL4Cdt2.
    Havens CG; Shobnam N; Guarino E; Centore RC; Zou L; Kearsey SE; Walter JC
    J Biol Chem; 2012 Mar; 287(14):11410-21. PubMed ID: 22303007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E3 ligase ligand chemistries: from building blocks to protein degraders.
    Sosič I; Bricelj A; Steinebach C
    Chem Soc Rev; 2022 May; 51(9):3487-3534. PubMed ID: 35393989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SIM-dependent enhancement of substrate-specific SUMOylation by a ubiquitin ligase in vitro.
    Parker JL; Ulrich HD
    Biochem J; 2014 Feb; 457(3):435-40. PubMed ID: 24224485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteolysis targeting peptide (PROTAP) strategy for protein ubiquitination and degradation.
    Zheng J; Tan C; Xue P; Cao J; Liu F; Tan Y; Jiang Y
    Biochem Biophys Res Commun; 2016 Feb; 470(4):936-40. PubMed ID: 26826379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure insights into the molecular mechanism of the interaction between UHRF2 and PCNA.
    Chen W; Wu M; Hang T; Wang C; Zhang X; Zang J
    Biochem Biophys Res Commun; 2017 Dec; 494(3-4):575-580. PubMed ID: 28951215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PROTAC-DB: an online database of PROTACs.
    Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
    Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
    He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
    Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
    Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of targeted protein degradation therapeutics.
    Chamberlain PP; Hamann LG
    Nat Chem Biol; 2019 Oct; 15(10):937-944. PubMed ID: 31527835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCNA-mediated stabilization of E3 ligase RFWD3 at the replication fork is essential for DNA replication.
    Lin YC; Wang Y; Hsu R; Giri S; Wopat S; Arif MK; Chakraborty A; Prasanth KV; Prasanth SG
    Proc Natl Acad Sci U S A; 2018 Dec; 115(52):13282-13287. PubMed ID: 30530694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PROTACs: A novel strategy for cancer therapy.
    Liu J; Ma J; Liu Y; Xia J; Li Y; Wang ZP; Wei W
    Semin Cancer Biol; 2020 Dec; 67(Pt 2):171-179. PubMed ID: 32058059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera.
    Kim K; Lee DH; Park S; Jo SH; Ku B; Park SG; Park BC; Jeon YU; Ahn S; Kang CH; Hwang D; Chae S; Ha JD; Kim S; Hwang JY; Kim JH
    Sci Rep; 2019 Dec; 9(1):19654. PubMed ID: 31873151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action.
    Riching KM; Mahan S; Corona CR; McDougall M; Vasta JD; Robers MB; Urh M; Daniels DL
    ACS Chem Biol; 2018 Sep; 13(9):2758-2770. PubMed ID: 30137962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PROTACs- a game-changing technology.
    Konstantinidou M; Li J; Zhang B; Wang Z; Shaabani S; Ter Brake F; Essa K; Dömling A
    Expert Opin Drug Discov; 2019 Dec; 14(12):1255-1268. PubMed ID: 31538491
    [No Abstract]   [Full Text] [Related]  

  • 19. New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation.
    Wang X; Feng S; Fan J; Li X; Wen Q; Luo N
    Biochem Pharmacol; 2016 Sep; 116():200-9. PubMed ID: 27473774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
    Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM
    Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.